Tango Therapeutics, Inc.
- Open
- 30.52
- Day high
- 31.48
- Day low
- 28.91
- Prev close
- 30.52
- Volume
- 3.4M
- Mkt cap
- $4.4B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 11.3
- P/S
- 77.5
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$3.0M over the last 3 months (0 open-market buys, 7 sales)
- 🏛Institutions accumulating (13F)
Tango Therapeutics, Inc. (TNGX) is a Healthcare company listed on NASDAQ. The stock is up 407% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 7 sales (SEC Form 4).
Tango Therapeutics, Inc. (TNGX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 8 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TNGX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-0.32 | $-0.32 | +0.0% | — | — |
| Mar 5, 2026 | $-0.32 | $-0.29 | +8.9% | — | — |
| Nov 4, 2025 | $0.01 | $0.13 | +1200.0% | $54M | +9578.2% |
| Feb 27, 2025 | $-0.32 | $-0.35 | -9.4% | $4M | -48.6% |
| Mar 18, 2024 | $-0.28 | $-0.32 | -14.3% | $5M | -34.1% |
| Nov 10, 2022 | $-0.32 | $-0.33 | -3.1% | $7M | +22.6% |
| Aug 10, 2022 | $-0.33 | $-0.28 | +15.2% | $6M | +2.0% |
| Aug 6, 2021 | — | $-0.05 | — | $18M | — |
| Mar 31, 2021 | — | $-0.42 | — | $9M | — |
| Nov 13, 2020 | — | $-0.31 | — | $11M | — |
TNGX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Crystal Adamofficer: President, R&D | Sell | 19,629 | $29.34 |
| Jul 2, 2026 | Crystal Adamofficer: President, R&D | Sell | 7,371 | $30.25 |
| Jul 2, 2026 | Crystal Adamofficer: President, R&D | Option | 27,000 | $5.20 |
| Jun 23, 2026 | Azelby Robertdirector | Grant | 5,740 | — |
| Jun 23, 2026 | Azelby Robertdirector | Grant | 35,910 | $27.97 |
| Jun 8, 2026 | Lee Sungdirector | Grant | 3,570 | $20.22 |
| Jun 8, 2026 | Ketchum John Bdirector | Grant | 4,000 | — |
| Jun 8, 2026 | Ketchum John Bdirector | Grant | 25,000 | $20.22 |
| Jun 8, 2026 | Calhoun Lesley Anndirector | Grant | 4,000 | — |
| Jun 8, 2026 | Calhoun Lesley Anndirector | Grant | 25,000 | $20.22 |
| Jun 8, 2026 | Rothenberg Macedirector | Grant | 4,000 | — |
| Jun 8, 2026 | Rothenberg Macedirector | Grant | 25,000 | $20.22 |
| Jun 8, 2026 | Lee Sungdirector | Grant | 570 | — |
| Jun 3, 2026 | Crystal Adamofficer: President, R&D | Option | 27,000 | $5.20 |
| Jun 3, 2026 | Crystal Adamofficer: President, R&D | Sell | 6,140 | $22.25 |
Source: TNGX SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.
See the full TNGX insider & 13F page →Tango Therapeutics, Inc. company profile
Overview
Tango Therapeutics, Inc. (NASDAQ:TNGX) is a biotechnology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company went public in September 2020 through a special purpose acquisition company (SPAC) merger. Tango focuses on discovering and developing targeted cancer therapies using a precision medicine approach called synthetic lethality, where drugs are designed to selectively kill cancer cells with specific genetic vulnerabilities while sparing healthy cells.
Business
Tango Therapeutics operates in the oncology biotechnology sector, developing small molecule drugs that target cancer cells with specific genetic mutations. The company's approach centers on synthetic lethality, a concept where cancer cells become dependent on certain proteins for survival when they have lost the function of other genes through mutation or deletion. By inhibiting these essential proteins, Tango's drugs can selectively kill cancer cells while leaving normal cells unharmed. The company's lead program is TNG908, a small molecule inhibitor targeting protein arginine methyltransferase 5 (PRMT5). This drug is designed to treat cancers that have deletions in the methylthioadenosine phosphorylase (MTAP) gene, which occurs in approximately 15% of all cancers. When MTAP is deleted, cancer cells become dependent on PRMT5 for survival, making them vulnerable to PRMT5 inhibition. Beyond TNG908, Tango is developing additional programs including a Ubiquitin-specific protease 1 (USP1) inhibitor for BRCA1 or BRCA2-mutant cancers, and Target 3 for STK11-mutant cancers. The company maintains a strategic collaboration with Gilead Sciences for discovering and developing additional cancer therapies. All of Tango's programs are currently in preclinical or early clinical development stages, representing a pipeline of potential treatments rather than commercially available products.
Revenue model
Tango Therapeutics generates revenue primarily through its strategic collaboration agreement with Gilead Sciences, which provides upfront payments, research funding, milestone payments, and potential future royalties. The company's current revenue comes from research and development services provided under this partnership, as evidenced by the $42 million in revenue reported for 2024, compared to $37 million in 2023. As a clinical-stage biotechnology company, Tango does not yet have commercial product sales. The company's future revenue model will depend on successfully advancing its drug candidates through clinical trials and regulatory approval. Potential revenue streams include product sales from commercialized drugs, licensing agreements with pharmaceutical partners, and additional milestone payments from existing and future collaborations. Several factors could significantly impact Tango's financial performance. Positive clinical trial results would likely attract additional partnership opportunities and increase the value of licensing deals. Regulatory approval timelines directly affect when the company might begin generating product revenue. Competition from other cancer drug developers targeting similar pathways could reduce market share and pricing power. Healthcare reimbursement policies will influence the commercial viability of approved products. Additionally, the company's cash burn rate and ability to secure additional funding will determine its capacity to advance programs through expensive late-stage clinical trials.
Competitive moat
Tango Therapeutics operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages. The company's primary differentiator lies in its synthetic lethality platform and specific expertise in identifying genetic vulnerabilities in cancer cells. However, this approach is not proprietary to Tango, as several other biotechnology companies and pharmaceutical giants are pursuing similar strategies. The company's intellectual property portfolio around its specific drug candidates provides some protection, but patents in biotechnology typically offer limited duration of exclusivity. Tango's partnership with Gilead Sciences provides validation and resources, but also creates dependency on a single major collaborator. The biotechnology industry is characterized by high barriers to entry due to regulatory requirements and substantial capital needs, but these barriers apply equally to all participants. Competition comes from both established pharmaceutical companies with greater resources and other biotechnology companies targeting similar cancer pathways. Large pharmaceutical companies like Roche, Merck, and Bristol Myers Squibb have significantly more resources for drug development and can potentially out-compete smaller biotechnology companies through superior clinical trial capabilities and regulatory expertise. Tango's competitive position is relatively weak, as the company lacks approved products, has limited financial resources compared to larger competitors, and operates in a field where scientific breakthroughs can quickly obsolete existing approaches. The company's survival depends heavily on successful clinical trial outcomes and continued partnership support.
Risks & safety
Tango Therapeutics presents significant financial risks typical of early-stage biotechnology companies, with limited margin of safety for investors. • Cash position: $58.4 million in cash and short-term investments as of Q1 2025, down from $69.5 million at year-end 2024 • Cash burn: Quarterly operating cash flow of -$41.7 million in Q1 2025, indicating high burn rate relative to cash reserves • Runway: At current burn rates, the company has approximately 3-4 quarters of cash remaining before requiring additional funding • Debt levels: Relatively low debt-to-equity ratio of 0.22, indicating manageable debt burden • Solvency risk: High, given rapid cash consumption and early-stage revenue generation • Valuation metrics: Trading at 0.91x book value and negative earnings multiples due to losses • Current ratio: Strong at 6.26, indicating good short-term liquidity position • Revenue dependency: Heavy reliance on Gilead partnership for current revenue, creating concentration risk The company will likely need to raise additional capital within the next 12-18 months to continue operations.
Recent development
Based on available financial data, Tango Therapeutics has been primarily focused on advancing its lead program TNG908 through clinical development while maintaining its strategic partnership with Gilead Sciences. The company's revenue has shown some growth, increasing from $25 million in 2022 to $42 million in 2024, reflecting expanded collaboration activities and milestone achievements. The company has been managing its cash resources carefully while continuing to invest in research and development activities. Operating expenses have remained relatively stable, with the company maintaining a disciplined approach to spending while advancing its clinical programs. The partnership with Gilead continues to provide both financial support and strategic validation for Tango's synthetic lethality approach. Recent financial performance indicates the company is progressing through typical biotechnology development milestones, with quarterly revenue fluctuations likely reflecting the timing of milestone payments and research activities under the Gilead collaboration. The company's ability to maintain its current cash runway while advancing TNG908 and other pipeline programs represents a key strategic focus.
TNGX company profile · for informational purposes only — not investment advice.
Track TNGX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free